Cantor Fitzgerald 10/20/20 : “Expecting positive Phase 3 data for COVID-19 opportunity. Lenzilumab could be the first antibody approved for cytokine storm associated with COVD-19, and HGEN could make up to $1B in sales in 2021”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.